<DOC>
	<DOCNO>NCT01005914</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study side effect give pegaspargase together combination chemotherapy see well work treat patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Pegaspargase Combination Chemotherapy Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate complete response rate patient newly diagnose acute lymphoblastic leukemia treat pegaspargase combination hyper-CVAD regimen comprise cyclophosphamide , dexamethasone , vincristine sulfate , doxorubicin hydrochloride , methotrexate , cytarabine . - To determine safety tolerability regimen patient . Secondary - To evaluate progression-free survival overall survival patient treat regimen . - To determine half-life pegaspargase administer combination hyper-CVAD regimen . - To monitor development neutralize antibody pegaspargase administer combination hyper-CVAD regimen . - To assess minimal residual disease flow cytometry end course 1A 1B . OUTLINE : This multicenter study . - Hyper-CVAD regimen ( course 1 , 3 , 5 , 7 ) : Patients receive cyclophosphamide IV 2-3 hour twice daily day 1-3 , dexamethasone IV day 1-4 11-14 , methotrexate intrathecally ( IT ) day 2 , doxorubicin hydrochloride IV 2 hour pegaspargase IV 1-2 hour day 4 , vincristine sulfate IV day 4 11 , cytarabine IT day 8 . - High-dose methotrexate/cytarabine regimen ( course 2 , 4 , 6 , 8 ) : Patients receive methotrexate IV continuously 24 hour day 1 , methylprednisolone IV twice daily day 1-3 , methotrexate IT day 2 , cytarabine IV 2 hour twice daily day 2 3 , pegaspargase IV 1-2 hour day 3 , cytarabine IT day 8 . Treatment repeat every 3-4 week 8 course absence disease progression unacceptable toxicity . Patients Philadelphia chromosome-positive disease also receive oral imatinib mesylate daily begin diagnosis . Patients complete 8 course chemotherapy candidate hematopoietic stem cell transplantation receive maintenance therapy study . Blood sample collect baseline periodically study pharmacokinetics neutralize antibody assay . After completion study therapy , patient follow every 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must newly diagnose ( untreated ) Acute Lymphoblastic Leukemia base bone marrow examination unless contraindication test perform . This include precursorB ALL , precursorT ALL , Philadelphia chromosome positive ALL . For reference , see criterion Center International Blood Marrow Transplant Research ( CIBMTR ) . &gt; 20 % blast bone marrow aspirate OR If bone marrow aspirate obtain , diagnosis acute leukemia establish pathologic diagnosis acute leukemia bone marrow biopsy OR A complete blood count document presence least 10,000 white blood cell ( WBC ) /μl least 20 % circulate blast Adults , 18 60 year age . Women child bear potential ( WOCBP ) must willing use adequate contraception avoid pregnancy duration study participation . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Adequate renal function define : Serum creatinine ≤ 2.0 x upper limit normal ( ULN ) institution Adequate hepatic function define : Total bilirubin ≤ 2.0 x ULN institution Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.0 x ULN institution Patient must ability understand willingness sign write informed consent document . The patient and/or patient 's legally authorized guardian must acknowledge consent treatment human subject study . Mature B ( Burkitt 's ) ALL exclude . An active malignancy ALL ( exception basal and/or squamous cell skin cancer curatively treat carcinoma cervix ) within 5 past year study entry . Documented central nervous system ( CNS ) involvement leukemia exclude . A diagnostic lumbar puncture part screen procedure . Severe pulmonary , renal , hepatic disease relate patient 's ALL exclude . Cardiac dysfunction define : Myocardial infarction within last 6 month study entry , Reduced leave ventricular function ejection fraction ≤50 % measure Multigated Acquisition ( MUGA ) scan echocardiogram study entry , Unstable angina , Unstable cardiac arrhythmia , New York Heart Association ( NYHA ) Class III IV heart failure , Electrocardiographic evidence acute ischemia active conduction system abnormality Known suspect human immunodeficiency virus ( HIV ) positive patient exclude study possible risk lethal infection treat marrow suppressive therapy . Any concurrent severe and/or uncontrolled medical condition ( e.g . uncontrolled diabetes , infection , hypertension , etc . ) psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Patients chemotherapy radiotherapy ALL prior enter study exclude . Hydroxyurea one dose intravenous vincristine allow prior registration patient convenience . Prior steroid therapy allowable , ≤5 day prior start regimen . Patients may receive investigational agent within last 30 day . WOCBP unwilling unable use acceptable method contraception entire study period . Pregnant lactate woman exclude study possible risk fetus infant . Women positive serum pregnancy test enrollment prior study drug administration exclude . Men whose sexual partner WOCBP , unwilling unable use acceptable contraceptive method avoid pregnancy partner entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>adult</keyword>
	<keyword>Philadelphia chromosome precursor ALL ,</keyword>
	<keyword>T-cell ALL</keyword>
	<keyword>untreated ALL</keyword>
</DOC>